Stockscreener 앱 받기
1.055
1.92%
0.015
전일 마감가:
$1.04
열려 있는:
$1.05
하루 거래량:
90,566
Relative Volume:
0.52
시가총액:
$73.50M
수익:
$391.70K
순이익/손실:
$-52.34M
주가수익비율:
-1.5071
EPS:
-0.7
순현금흐름:
$-45.92M
1주 성능:
-7.83%
1개월 성능:
-10.92%
6개월 성능:
-65.92%
1년 성능:
-67.68%
1일 변동 폭
$1.01
$1.07
1주일 범위
$0.9877
$1.19
52주 변동 폭
$0.68
$4.10
Ovid Therapeutics Inc Stock (OVID) Company Profile
명칭
Ovid Therapeutics Inc
전화
212-776-4381
주소
441 NINTH AVENUE, 14TH FLOOR, NEW YORK, NY
OVID을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
| OVID | 1.055 | 73.50M | 391.70K | -52.34M | -45.92M | -0.70 |
| VRTX | 449.38 | 115.43B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 744.60 | 82.04B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 595.35 | 35.30B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 246.78 | 32.04B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 108.16 | 24.89B | 3.30B | -501.07M | 1.03B | 11.54 |
Ovid Therapeutics Inc Stock (OVID) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2021-04-20 | 다운그레이드 | Cantor Fitzgerald | Buy → Neutral |
| 2021-03-03 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
| 2020-12-02 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2020-12-02 | 다운그레이드 | JMP Securities | Mkt Outperform → Mkt Perform |
| 2019-09-04 | 개시 | RBC Capital Mkts | Outperform |
| 2018-04-20 | 개시 | Ladenburg Thalmann | Buy |
모두보기
Ovid Therapeutics Inc 주식(OVID)의 최신 뉴스
B. Riley Decreases Earnings Estimates for Ovid Therapeutics - Defense World
Equities Analysts Offer Predictions for OVID FY2024 Earnings - MarketBeat
Fragile X Syndrome (Fxs) Treatment Market Growth Overview - openPR
Wedbush Forecasts Weaker Earnings for Ovid Therapeutics - Defense World
Equities Analysts Issue Forecasts for OVID FY2024 Earnings - Defense World
William Blair Has Positive Outlook for OVID FY2024 Earnings - MarketBeat
RFK Jr vow to purge FDA sets up collision with Big Pharma - Reuters
Ovid Therapeutics Inc (OVID) Quarterly 10-Q Report - Quartzy
William Blair Analysts Increase Earnings Estimates for OVID - MarketBeat
Ovid Therapeutics earnings beat, revenue topped estimates By Investing.com - Investing.com Canada
Ovid Therapeutics (OVID) Reports Q3 Loss, Tops Revenue Estimates - Yahoo Finance
Ovid Therapeutics Reports Business Updates and Third Quarter 2024 Financial Results - GlobeNewswire
US Penny Stocks To Watch This November 2024 - Simply Wall St
Ovid Therapeutics to Host Investor Event - GlobeNewswire
Ovid Therapeutics Inc. (NASDAQ:OVID) Receives $4.04 Consensus Target Price from Brokerages - MarketBeat
Layoff Tracker: Sage Therapeutics Will Lay Off 33% of Employees - BioSpace
Ovid Therapeutics (STU:1OT) Cyclically Adjusted Revenue per Share : €0.00 (As of Jun. 2024) - GuruFocus.com
Ovid Therapeutics (STU:1OT) Revenue per Share : €0.01 (TTM As of Jun. 2024) - GuruFocus.com
Patentability And Therapeutic Efficacy: Analysis Of Section 3(D) In Ovid Therapeutics v/s Controller Of Patents 2024 - Legal Service India
Ovid Therapeutics Inc. (NASDAQ:OVID) Given Consensus Rating of “Moderate Buy” by Brokerages - Defense World
Ovid Therapeutics Inc. (NASDAQ:OVID) Given Consensus Rating of "Moderate Buy" by Brokerages - MarketBeat
ROTH to Host 3rd Annual Healthcare Opportunities Conference on October 9 in New York City - The Manila Times
Marinus Pharmaceuticals' patent upheld by PTAB - Investing.com
Rhumbline Advisers Sells 12,851 Shares of Ovid Therapeutics Inc. (NASDAQ:OVID) - Defense World
Patentability And Therapeutic Efficacy: Analysis Of Section 3(D) In Ovid Therapeutics v/s Controller Of Patents (2024) - Legal Service India
Ovid Therapeutics stock retains Buy rating from H.C. Wainwright By Investing.com - Investing.com Canada
Ovid Therapeutics stock retains Buy rating from H.C. Wainwright - Investing.com
Will Ovid Therapeutics (NASDAQ:OVID) Spend Its Cash Wisely? - Yahoo Finance
Ovid Therapeutics (NASDAQ:OVID) Stock Rating Reaffirmed by HC Wainwright - MarketBeat
HC Wainwright Reaffirms “Buy” Rating for Ovid Therapeutics (NASDAQ:OVID) - Defense World
1,400,191 Shares in Ovid Therapeutics Inc. (NASDAQ:OVID) Bought by Driehaus Capital Management LLC - MarketBeat
Ovid stock gets boost from promising OV329 toxicity profileB.Riley - Investing.com
Ovid reports promising safety profile for epilepsy drug OV329 - Investing.com
Ovid Therapeutics Presents Pre-Clinical Study Results - GlobeNewswire
Ovid Therapeutics Presents Pre-Clinical Study Results Demonstrating OV329 Does Not Accumulate in Animal Eyes in Contrast with Vigabatrin - StockTitan
Neurological diseases index falls; Sarepta and Intra-Cellular report gains - BioWorld Online
Lombard Odier Asset Management USA Corp Has $236,000 Stock Position in V2X, Inc. (NYSE:VVX) - Defense World
Murchinson Ltd. Trims Stock Holdings in Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) - MarketBeat
Market Resilience: Vor Biopharma Inc (VOR) Finishes Weak at 0.83, Down -7.78 - The Dwinnex
Lombard Odier Asset Management Europe Ltd Makes New Investment in Option Care Health, Inc. (NASDAQ:OPCH) - Defense World
The Attractiveness of Investing In OmniAb Inc (OABI) is Growing - Knox Daily
Oxford Biomedica Sees Robust Growth in 2024 - TipRanks
Olema Pharmaceuticals (NASDAQ:OLMA) Shares Up 6.3% - Defense World
Victory Capital Management Inc. Has $991,000 Holdings in Option Care Health, Inc. (NASDAQ:OPCH) - Defense World
DCF Advisers LLC Boosts Stock Position in Ovid Therapeutics Inc. (NASDAQ:OVID) - Defense World
Ovid Therapeutics (NASDAQ:OVID) Shares Cross Below Fifty Day Moving Average of $1.06 - MarketBeat
After epilepsy setback, Ovid charges confidently ahead in CNS - Yahoo Finance
Q3 2025 EPS Estimates for ModivCare Inc. (NASDAQ:MODV) Reduced by Analyst - MarketBeat
Victory Capital Management Inc. Increases Position in OneMain Holdings, Inc. (NYSE:OMF) - Defense World
Ovid Therapeutics (NASDAQ:OVID) Stock Passes Below 50 Day Moving Average of $1.06 - Defense World
Checking in on OmniAb Inc (OABI) after recent insiders movement - Knox Daily
Ovid Therapeutics Inc (OVID) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.80%
0.42%
자본화:
|
볼륨(24시간):